Intervention not reported
BEV+HSPPC96 1 RCTs; 53 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+HSPPC96 1 RCTs; 53 participants) (low certainty).
1 finding from 1 review
- Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyRR 1.01 [0.33, 3.1]1 study · 96 participantsLow